免疫疗法(APC8015 Provenge)针对前列腺酸性磷酸酶能引起持久缓解转移性前列腺癌androgen-independent:第二阶段试验。

文章的细节

引用
复制到剪贴板

伯奇PA, Croghan GA,加斯蒂内奥哒,琼斯,考尔JS, Kylstra JW,理查森RL,酮FH, Vuk-Pavlovic年代

免疫疗法(APC8015 Provenge)针对前列腺酸性磷酸酶能引起持久缓解转移性前列腺癌androgen-independent:第二阶段试验。

前列腺。2004年8月1;60 (3):197 - 204。

PubMed ID
15176049 (在PubMed
]
文摘

背景:前列腺癌是美国男性最常诊断恶性肿瘤,然而治疗转移性androgen-independent形式仍然不足。这要求开发新免疫疗法等疗法。在这第二阶段试验,我们决定抗原呈递细胞(apc)的疗效装满PA2024,重组融合蛋白含有前列腺酸性磷酸酶(PAP)和gm - csf。方法:我们选取21个病人在组织学证明androgen-independent前列腺癌,可以评估放射性核素骨扫描或电脑断层扫描。从leukapheresis APC8015准备产品;它包含了自体CD54-positive PA2024-loaded装甲运兵车外加剂的单核细胞,巨噬细胞,B细胞和T细胞。APC8015被注入静脉注射两次,2周。第二个输液两周后,患者接受3皮下注射1.0毫克的PA2024 1个月。我们监控病人的身体状况,免疫反应,和实验参数。结果:19例可以评估对治疗的反应。 The median time to progression was 118 days. Treatment was tolerated reasonably well; most adverse effects were secondary to APC8015 and were NCI Common Toxicity Criteria Grade 1-2. Four of the 21 patients reported Grade 3-4 adverse events. Two patients exhibited a transient 25-50% decrease in prostate-specific antigen (PSA). For a third patient, PSA dropped from 221 ng/ml at baseline to undetectable levels by week 24 and has remained so for more than 4 years. In addition, this patient's metastatic retroperitoneal and pelvic adenopathy has resolved. PBMC collected from patients for at least 16 weeks proliferated upon in vitro stimulation by PA2024. For the patient with responsive disease, PBMC could be stimulated for 96 weeks. CONCLUSIONS: This study demonstrates a definite clinical response of androgen-independent prostate cancer to APC immunotherapy. Currently we are studying this mode of therapy in Phase 3 trials.

beplay体育安全吗DrugBank数据引用了这篇文章

药物
药物靶点
药物 目标 类 生物 药理作用 行动
Sipuleucel-T 前列腺酸性磷酸酶 蛋白质 人类
是的
其他
 细节